<DOC>
	<DOCNO>NCT02023151</DOCNO>
	<brief_summary>This research do test whether difference blood cell baseline ( start study ) use predict well omalizumab work patient . Omalizumab ( Xolair ) drug approve U.S. Food Drug Administration ( FDA ) treat asthma . Studies show omalizumab improves symptom asthma people experience well improvement others .</brief_summary>
	<brief_title>Predicting Clinical Response Omalizumab With Anti-IgE Ab Response Syk Expression Basophils</brief_title>
	<detailed_description>From therapeutic perspective , study determine whether change peripheral blood basophil response crosslinking anti-IgE Ab treatment omalizumab predict clinical efficacy treatment drug . Secondary outcome measure would focus whether start level anti-IgE-mediated histamine release , change syk expression start level would sufficient predict clinical outcome . The study single-site trial evaluate utility baseline basophil measure predict efficacy subcutaneously administer omalizumab add-on therapy treatment adult patient 18âˆ’75 year old diagnose moderate severe asthma accord current approve guideline . Patients treat omalizumab accord standard FDA approve dose table period 16 week .</detailed_description>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients moderatetosevere asthma ; male female age 1875 symptomatic despite treatment inhaled corticosteroid also asthma duration &gt; 1 year . Positive blood test least one common allergen ( include must mite , D. F. D. P. , cockroach , dog cat ) Serum IgE within bound dose table ( &gt; 30 IU/ml &lt; 700 IU/ml ) Reversibility &gt; 12 % within 30 minute administration albuterol history reversibility past history positive methacholine past Baseline FEV1 &gt; 0 % &lt; 80 % predict Treatment 400 800 ug day beclomethasone dipropionate equivalent . Patients must willing give write informed consent able adhere dose visit schedule meet trial requirement . Patients exclude prior sensitivity omalizumab , acute respiratory tract infection prior runin period , need regular Bagonist use . Treatment investigational agent within 30 day screen Previously treat omalizumab within year prior screen Treatment 1 month prior screening : hydroxychloroquine , methotrexate , cyclosporine , cyclophosphamide , intravenous immunoglobulin G , plasmapheresis Clinically relevant laboratory anomaly screen include individual reduce hematocrit ( &lt; 32 % ) , WBC count ( 2400/microliter ) , platelet count ( &lt; 75000/microliter ) , increase creatinine ( &gt; 141.4 micromolar/L ) , AST ( &gt; 100 IU/L ) . Patients current malignancy , history malignancy , currently workup suspect malignancy , bleed disorder . History medical condition unstable Inability comply study followup procedure Patients may take systemic corticosteroid within 2 week prior screening\ Women childbearing potential pregnant nursing mother , childbearing potential ( postmenarche ) practice acceptable form contraception ( determine site investigator ) Individuals body weight le 30 kg great 150 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>